RxDoctor Payments DataLook up a doctor →

Armando Garcia, MD

Hematology & Oncology · Rio Piedras, PRNPI 1346347515

Payments from drug & device makers

$38,893in general payments, 2019–2025

Across 1,642 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • AstraZeneca$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Amgen$3K
  • PBG Puerto Rico LLC$2K
  • Eli Lilly Export S.A. Puerto Rico Branch$2K
  • plus $15K from 43 others

What the payments were for

  • Consulting fees$2,3806%
  • Travel & lodging$120%
  • Food & beverage$34,89990%
  • Education$1,6024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,893 in reported general payments places this provider in the 70th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$27,152
Medicare patients
17
Services billed
11,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib61$993,587
ErleadaApalutamide43$589,825
JakafiRuxolitinib Phosphate34$582,751
InlytaAxitinib19$388,804
XtandiEnzalutamide18$253,024
VerzenioAbemaciclib13$199,471
RevlimidLenalidomide15$186,997
NinlaroIxazomib Citrate11$145,587
RetacritEpoetin Alfa-Epbx42$30,825
Imatinib Mesylate20$11,935
XareltoRivaroxaban13$7,471
Sucralfate24$4,911
Anastrozole282$4,837
Hydroxyurea42$2,470
Dexamethasone116$2,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$7,062$597,29556 claims
Incyte CorporationJakafi$749$582,75134 claims
PfizerInlyta, Retacrit$245$419,62961 claims
Astellas Pharma US IncXtandi$349$253,02418 claims
Lilly USA, LLCVerzenio$320$199,47113 claims
Bristol Myers SquibbRevlimid$73$186,99715 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$656$145,58711 claims
AbbVieSynthroid$1,924$1,33425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →